Literature DB >> 3345623

Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine.

J van Harten1, P van Brummelen, M T Lodewijks, M Danhof, D D Breimer.   

Abstract

Pharmacokinetics, diastolic blood pressure, and heart rate after oral and intravenous nisoldipine were studied in eight healthy subjects without and with cotreatment of cimetidine in a four-way crossover design. After intravenous infusion, elimination half-life (t1/2) was 4.0 +/- 2.3 hours, systemic clearance (CL) was 0.83 +/- 0.17 L/min, and volume of distribution was 1.6 +/- 0.6 L/kg. After oral nisoldipine, t1/2 was 3.8 +/- 1.3 hours and systemic availability was 3.9% +/- 3.5%. During cimetidine, t1/2 and CL were not different. Systemic availability increased to 5.7% +/- 2.8%. After all nisoldipine treatments a significant decrease in supine diastolic blood pressure (mean 10% to 16%) and increase in heart rate (mean 22% to 44%) were observed. Hemodynamic effects until 2 hours after nisoldipine administration could be fitted to a sigmoidal Emax model. At times after 2 hours a second effect peak was observed. Cimetidine inhibits the metabolism of nisoldipine but has no significant influence on hemodynamic parameters.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3345623     DOI: 10.1038/clpt.1988.40

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  14 in total

1.  Influence of the H2-receptor antagonists cimetidine and ranitidine on the pharmacokinetics of nimodipine in healthy volunteers.

Authors:  W Mück; W Wingender; M Seiberling; E Woelke; K D Rämsch; J Kuhlmann
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Comparison of information on the pharmacokinetic interactions of Ca antagonists in the package inserts from three countries (Japan, USA and UK).

Authors:  Mitsuo Saito; Mutsuko Hirata-Koizumi; Shinji Miyake; Ryuichi Hasegawa
Journal:  Eur J Clin Pharmacol       Date:  2005-07-23       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of calcium antagonists. An update.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

4.  The contribution of nisoldipine-induced changes in liver blood flow to its pharmacokinetics after oral administration.

Authors:  J van Harten; J Burggraaf; M Danhof; P van Brummelen; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

5.  Influence of renal function on the pharmacokinetics and cardiovascular effects of nisoldipine after single and multiple dosing.

Authors:  J van Harten; J Burggraaf; P van Brummelen; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

Review 6.  Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Authors:  H A Friedel; E M Sorkin
Journal:  Drugs       Date:  1988-12       Impact factor: 9.546

Review 7.  Calcium antagonists. Drug interactions of clinical significance.

Authors:  T Rosenthal; D Ezra
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

8.  Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist.

Authors:  M R Goldberg; M W Lo; T E Bradstreet; M A Ritter; P Höglund
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

9.  General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.

Authors:  Yoshiyuki Ohno; Akihiro Hisaka; Hiroshi Suzuki
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

10.  Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration.

Authors:  J van Harten; P van Brummelen; J H Wilson; M T Lodewijks; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.